Nam Doo Kim

USPTO Granted Patents = 10 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 9.7

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Daegu, KR (2019 - 2021)
Incheon, KR (2015 - 2024)

Company Filing History:

Daegu-gyeongbuk Medical Innovation Foundation

patents

1 out of 321

Korea Research Institute of Bioscience and Biotechnology

patents

4. 1 out of 235

Daegu Gyeongbuk Institute of Science and Technology

National Cancer Center

patents

7. 1 out of 122

Samsung Life Public Welfare Foundation

patents

8. 1 out of 2,164

Korea Institute of Science and Technology

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12281121 - N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer (2025-04-21),

2. 12157730 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-12-03),

3. 12152021 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-11-26),

4. 12037330 - Heteroaryl derivative compounds, and uses thereof (2024-07-16),

5. 11466000 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2022-10-11),

6. 11208412 - Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease (2021-12-28),

7. 11117892 - Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases (2021-09-14),

8. 10870647 - Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer (2020-12-22),

9. 10442796 - 2,3,5-substituted thiophene compound as protein kinase inhibitor (2019-10-15),

10. 9216981 - Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient (2015-12-22),

Title: The Innovative Mind of Nam Doo Kim

Introduction: Nam Doo Kim, an accomplished inventor based in Daegu, South Korea, has made significant contributions to the field of pharmaceutical innovation. With a portfolio of 10 patents, Kim has focused his research on developing compounds aimed at combating cancer, showcasing his dedication to advancing medical science.

Latest Patents: Among his recent innovations, Kim has developed several noteworthy patents, including an N-containing heteroaryl derivative specifically designed for the prevention or treatment of cancer. This derivative demonstrates high inhibitory activity against various protein kinases, particularly the ret proto-oncogene (RET). It has shown remarkable efficacy in inhibiting the proliferation of medullary thyroid cancer cells and lung cancer cells expressing RET fusion genes, marking a substantial step forward in targeted cancer therapies.

Another patent highlights a unique 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, which serves as a pharmaceutical composition for cancer treatment. This compound possesses significant inhibitory action against epidermal growth factor receptor (EGFR) variants and has proved particularly effective on lung cancer cell lines, emphasizing its potential in cancer treatment strategies.

Career Highlights: Throughout his career, Nam Doo Kim has focused on the intersection of pharmaceutical development and innovative research. His work with Voronoi Inc. has played a critical role in fostering advancements in medical technologies, while his tenure at the Daegu-Gyeongbuk Medical Innovation Foundation has further allowed him to explore new therapeutic avenues for cancer treatment.

Collaborations: Kim has collaborated with notable colleagues, including Jung Beom Son and Yi Kyung Ko, to enhance his research efforts and drive forward his initiatives in the pharmaceutical landscape. These partnerships have contributed to his success in developing effective cancer treatments.

Conclusion: Nam Doo Kim stands out as a leading innovator in the field of pharmaceuticals, particularly in the fight against cancer. His dedication to research and development, evidenced by his impressive portfolio of patents, reflects his commitment to improving patient outcomes and advancing medical science. As he continues to expand his contributions, Nam Doo Kim remains a vital figure in the realm of cancer treatment innovation.

This text is generated by artificial intelligence and may not be accurate.